The Boston Deals You Missed During the Holidays: Cash for Kala Pharma, Funds for ViewFinity, Silver for SCVNGR, & More

1/4/10

(Page 2 of 2)

of the largest tax breaks are going to some of the state’s biggest biotech firms, such as Biogen Idec (NASDAQ:BIIB), Genzyme (NASDAQ:GENZ), and Shire Human Genetic Therapies.

—A top-secret biotech startup called Kala Pharmaceuticals raised $2 million in an equity round, according to an SEC filing. Next to nothing is known about Boston-based Kala, but the firm’s board includes renowned MIT bioengineering professor Bob Langer and former MIT researcher Justin Hanes, who is now a professor of chemical and biomolecular engineering at Johns Hopkins University. New York-based Lux Capital’s Robert Paull is the founding CEO of Kala.

—Mobile gaming startup SCVNGR of Boston raised $4 million in a second round of financing, according to a December 24 regulatory filing. Mass High Tech reported that the cash came from Google Ventures and return investor Highland Capital Partners; Google Ventures’ Rich Miner joined SCVNGR’s board as part of the deal.

—Billerica, MA-based directory assistance firm Jingle Networks raised $6.75 million in its fifth round of funding, according to a regulatory filing.

—Mobile display maker Pixtronix of Andover, MA, raised $19 million in equity and warrants, according to a report in Mass High Tech based on a regulatory filing.

—Amicas (NASDAQ: AMCS), a medical imaging and information management company in Boston, agreed to be acquired by an affiliate of private equity firm Thoma Bravo for roughly $217 million. Amicas shareholders, who will have to approve the deal, would receive $5.35 in cash per share, a 24 percent premium over the average closing price of the stock in the 30 trading days ending December 24, 2009.

—A New Years Eve regulatory filing showed that Boston-based Digital Lumens has raised $5 million. The startup, a developer of high-efficiency lighting, lists Flybridge Capital Partners, Stata Venture Partners, and Black Coral Capital as its investors.

Single Page Currently on Page: 1 2 previous page

By posting a comment, you agree to our terms and conditions.